Big Pharma chiefs balk at bidding against Roche for Illumina

Other major pharma chiefs don't see the same opportunity in acquiring Illumina ($ILMN) as does Roche CEO Severin Schwan, whose company's $5.7 billion hostile takeover bid for the maker of DNA sequencers has generated buzz about other potential suitors. Based on their recent remarks on the situation, count out Sanofi ($SNY) CEO Chris Viehbacher and Novartis ($NVS) CEO Joe Jimenez. "It's just not the risk profile we're looking for. It could pay off well or there's a big downside," Viehbacher said, as quoted by Reuters. "You need to be part of new technologies but I think partnership is the way to go." Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.